Sonoma Pharmaceuticals Launches New Ceramax™ Skin Barrier Lotion with Skin-Enriching Lipogrid Technology™
2018年10月17日 - 8:05PM
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty
pharmaceutical company that develops and markets unique and
effective solutions for the treatment of dermatological conditions
and advanced tissue care, today announced the launch of a new
Ceramax™ Skin Barrier Lotion. This new product complements Sonoma’s
current Ceramax Skin Barrier Cream.
“We continue to receive positive physician and
patient feedback on our current Ceramax cream, which we launched
two years ago,” said Tom Devine, Sonoma Pharmaceutical’s
dermatology division general manager. “We are now expanding this
product line for those patients who prefer prescription-level
barrier protection benefits in a lighter lotion formula.”
Both Ceramax products contain skin-enriching
technology that helps manage dry itchy skin, minor skin
irritations, rashes and inflammation caused by various skin
conditions, including atopic dermatitis and allergic contact
dermatitis. This technology contains selected lipids and a lipid
precursor designed to easily penetrate the bilayers of the skin by
blending with the natural lipid building blocks.
Ceramax lotion will be available via dermatologist
prescription throughout the United States beginning in late
October.
About Atopic DermatitisAccording
to a report by Research and Markets, the global atopic dermatitis
treatment market in 2016 was valued at $4.04 billion U.S. It is
expected to grow to $7.66 billion by 2025, expanding at a CAGR of
7.4% from 2017 to 2025.
Symptoms of atopic dermatitis are characterized by
itchy skin, which can lead to rash, redness, swelling, crusting and
scaling. The disease affects up to 20 percent of infants and young
children, who continue to have symptoms as adults with significant
impact on their quality of life. The exact cause is unknown, but
genetics are considered a key factor.
Topical corticosteroids (such as hydrocortisone,
betamethasone, and fluticasone) are the most common treatment for
atopic dermatitis. As eczema tends to be persistent, most people
will have to use topical steroids on and off for many years. If
used continuously topical steroids may lose their effectiveness
after a few weeks. This is known as tachyphylaxis.
About Sonoma Pharmaceuticals,
Inc.Sonoma is a specialty pharmaceutical company that
develops and markets unique and effective solutions for the
treatment of dermatological conditions and advanced tissue care.
The company’s products, sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept
for historical information herein, matters set forth in this
press release are forward-looking within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995, including statements about the commercial and technology
progress and future financial performance of Sonoma
Pharmaceuticals, Inc. and its subsidiaries (the “Company”). These
forward-looking statements are identified by the use of words such
as “licensed,” “marketed,” and “branded,” among others.
Forward-looking statements in this press release are subject to
certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary,
including such risks that regulatory clinical and
guideline developments may change, scientific data may not be
sufficient to meet regulatory standards or receipt of required
regulatory clearances or approvals, clinical results may not
be replicated in actual patient settings, protection offered
by the Company’s patents and patent applications may be
challenged, invalidated or circumvented by its
competitors, the available market
for the Company’s products will not be as large as
expected, the Company’s products will not be able to penetrate
one or more targeted markets, revenues will not be sufficient
to fund further development and clinical studies, as well as
uncertainties relative to varying product formulations and a
multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals®, Ceramax™ and Lipogrid
Technology™ are registered trademarks of Sonoma Pharmaceuticals,
Inc. All other trademarks and service marks are the property of
their respective owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.Bob MillerCFO+1 (925) 787-6218
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
過去 株価チャート
から 5 2024 まで 6 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
過去 株価チャート
から 6 2023 まで 6 2024